Cargando…

Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis

BACKGROUND: When multiple treatments are available, network meta-analysis can synthesize evidence and rank their relative profile in terms of effectiveness and/or safety. We applied this approach to the safety of subcutaneous biologicals used in the treatment of moderate to severe psoriasis. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messori, Andrea, Trippoli, Sabrina, Fadda, Valeria, Maratea, Dario, Marinai, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883196/ https://www.ncbi.nlm.nih.gov/pubmed/27747609 http://dx.doi.org/10.1007/s40801-014-0006-1

Ejemplares similares

Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methods
por: Messori, Andrea, et al.
Publicado: (2015)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
por: Messori, Andrea, et al.
Publicado: (2015)

New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?
por: Messori, Andrea, et al.
Publicado: (2014)

Handling the procurement of prostheses for total hip replacement: description of an original value based approach and application to a real-life dataset reported in the UK
por: Messori, Andrea, et al.
Publicado: (2017)

Relationship Between Price and Diagnosis-Related Group Tariff for Medical Devices Assessed by a Regional Health Technology Assessment Committee
por: Trippoli, Sabrina, et al.
Publicado: (2022)

Managing Tenders in the Procurement of Advanced Medical Devices: An Original Model Based on the Net Monetary Benefit Combined With Three Clinical Endpoints
por: Messori, Andrea, et al.
Publicado: (2023)

Simplified figure to present direct and indirect comparisons: Revisiting the graph 10 years later
por: Fadda, Valeria, et al.
Publicado: (2021)

A Comparison of Statistical Analysis Between "Real" Patients Reported in Kaplan-Meier Curves and "Reconstructed" Patients Estimated Through the IPDfromKM Method: Analysis of Eight Trials Evaluating Catheter Ablation of Ventricular Tachycardia
por: Messori, Andrea, et al.
Publicado: (2023)

Long-term outcomes in chronic obstructive pulmonary disease patients: exploring the effects of inhalatory devices and their influence on the outcome
por: Fadda, Valeria, et al.
Publicado: (2016)

Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method
por: Trippoli, Sabrina, et al.
Publicado: (2022)

Early and intermediate survival after transcatheter aortic valve implantation: systematic review and meta-analysis of 14 studies
por: Messori, Andrea, et al.
Publicado: (2013)

The limitations of observational studies on the treatment of severe sepsis – authors' response
por: Messori, Andrea, et al.
Publicado: (2002)

Value-based procurement of prostheses for total knee replacement
por: Messori, Andrea, et al.
Publicado: (2018)

Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy
por: Messori, Andrea, et al.
Publicado: (2022)

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
por: Golhen, Klervi, et al.
Publicado: (2022)

Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
por: Chiumente, Marco, et al.
Publicado: (2016)

The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies
por: Messori, Andrea, et al.
Publicado: (2021)

Antithrombin III in patients admitted to intensive care units: a multicenter observational study
por: Messori, Andrea, et al.
Publicado: (2002)

Estimation of Value-Based Price for 48 High-Technology Medical Devices
por: Hyeraci, Giulia, et al.
Publicado: (2023)

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis
por: Geng, Wenjun, et al.
Publicado: (2018)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
por: Membrive Jiménez, Cristina, et al.
Publicado: (2021)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis
por: Zhu, Teng, et al.
Publicado: (2022)

Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability
por: Manalo, Iviensan F, et al.
Publicado: (2015)

Therapy of moderate and severe psoriasis
por: Claes, Christa, et al.
Publicado: (2006)

Moderate to severe psoriasis treatment challenges through the era of biological drugs
por: Vide, Júlia, et al.
Publicado: (2017)

Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
por: Barker, Jonathan, et al.
Publicado: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
por: Messori, A, et al.
Publicado: (2001)

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses
por: Baker, Erica L., et al.
Publicado: (2012)

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study
por: Gargiulo, Luigi, et al.
Publicado: (2022)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tobbuce8jpd6jcof8flmjdn576